A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer
Prostate Cancer|Salivary Gland Cancer|Endometrial Cancer|Squamous Cell Carcinoma of the Cervix|Breast Cancer|Ovarian Cancer
DRUG: OPB-111001
Maximum tolerated dose / Recommended Phase 2 dose; Tolerability, after 2 or 6 weeks depending on study part; continously
Pharmacokinetic parameters for OPB-111001 and its metabolites, Frequent sampling during Cycle 1 to 3, D1 only from Cycle 4 onwards, repeatedly until end of study (average of 3 months assumed)|Assessment of antitumor activity as defined by Response Evaluation Criteria in Solid Tumours (RECIST), repeatedly every 8th week until end of study (average of 3 months assumed)|Prostate-specific antigen (PSA) response in patients with prostate cancer, repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed)|Cancer antigen 125 (CA 125) response in patients with ovarian cancer, repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed)|Time to treatment failure, At end of study (after average of 3 months assumed)
The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer